insilico.com

Insilico Medicine and Servier Achieve First Milestone in AI-Driven R&D Collaboration, Triggering An undisclosed Milestone Payment

• Two programs under the multi-year R&D collaboration have initiated and completed target nomination since its early 2026 announcement. • Insilico reached the first R&D milestone using its proprietary ...
insilico.com

AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases

• Sustained Boost in AI-Driven R&D Productivity: ISM9546 marks Insilico Medicine's 35th preclinical candidate (PCC) nominated since 2021 and its 11th PCC within the first 10 months of 2026 alone, ...
insilico.com

Pharma.AI Fall 2026 Release Recap: Transforming Drug Discovery and Development Through Specialized Models and AI Agents

Insilico has a connected set of capabilities for adapting AI to scientific work. MMAI Gym develops specialized models; benchmarking helps researchers assess their performance; Generative Biologics, ...
insilico.com

ARDD 2026 Signals a New Era for Longevity Biotechnology as Frontier AI, Big Pharma, and Scientific Pioneers Converge at Harvard

The convergence of frontier artificial intelligence, large-scale biological data, and pharmaceutical innovation is opening new possibilities for understanding human aging, predicting disease, and ...
insilico.com

Dual-purpose therapeutic targets predicted using AI

Insilico Medicine has successfully created a unique approach to identifying potential therapeutic dual-purpose targets for aging and age-associated diseases with its PandaOmics software — an ...
insilico.com

Commercialization Roadmap Validated with Three-digit Million-dollar Revenue: Insilico Medicine Announces Interim Results for the First Half of 2026

Insilico Medicine (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently released its interim results report for 2026. The report shows that the ...
insilico.com

Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery

Cambridge, MA, July 2, 2026 — Insilico Medicine (“Insilico” HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to ...
insilico.com

Insilico Medicine Announces Global R&D Collaboration with Lilly

AI-driven collaboration includes an exclusive worldwide license for a portfolio of programs spanning multiple therapeutic areas. Insilico Medicine (“Insilico”, HKEX: 3696), a clinical-stage ...
insilico.com

Liquid AI and Insilico Medicine Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery

Liquid AI and Insilico Medicine today announced a partnership that creates lightweight scientific foundation models for pharmaceutical research. The collaboration has produced LFM2-2.6B-MMAI (v0.2.1), ...
insilico.com

Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

The GENESIS-IPF Phase IIa study showed manageable safety and tolerability, with the 60 mg once-daily arm demonstrating mean forced vital capacity improvement of +98.4 mL at 12 weeks CAMBRIDGE, Mass., ...
insilico.com

Insilico Medicine Announces 2025 Annual Results, Redefining Value Delivery in AI-Powered Drug Discovery

On the evening of March 29, 2026, Insilico Medicine (“Insilico”, HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI) and automation, announced its ...
insilico.com

Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development

Combines Insilico’s Pharma.AI platform with Bora’s global development, manufacturing, quality, and commercialization capabilities to explore a next-generation drug innovation model Insilico Medicine ( ...